Movement Disorders, 2015, Vol.30(7), p.919(9)
To purchase or authenticate to the full-text of this article, please visit this link: http://onlinelibrary.wiley.com/doi/10.1002/mds.26170/abstract Byline: Daniel Weintraub, Tanya Simuni, Chelsea Caspell-Garcia, Christopher Coffey, Shirley Lasch, Andrew Siderowf, Dag Aarsland, Paolo Barone, David Burn, Lama M. Chahine, Jamie Eberling, Alberto J. Espay, Eric D. Foster, James B. Leverenz, Irene Litvan, Irene Richard, Matthew D. Troyer, Keith A. Hawkins, Keywords: anxiety; apathy; cognition; depression; impulse control disorder; Parkinson's disease; psychosis Abstract This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). Background Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. Methods Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. Results Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P〈0.001), with twice as many (14% vs. 7%) meeting criteria for clinically significant depressive symptoms. The PD patients also experienced more anxiety (P〈0.001) and apathy (P〈0.001) than HCs. Psychosis was uncommon in PD (3%), and no between-group difference was seen in ICD symptoms (P=0.51). Conclusions Approximately 10% of PD patients in the early, untreated disease state met traditional criteria of CI, which is a lower frequency compared with previous studies. Multiple dopaminergic-dependent NPS are also more common in these patients compared with the general population, but others associated with dopamine replacement therapy are not or are rare. Future analyses of this cohort will examine biological predictors and the course of CI and NPS. [c] 2015 International Parkinson and Movement Disorder Society Article Note: Funding agencies: The study is funded by the Michael J. Fox Foundation (MJFF). The MJFF designed the study and is overseeing its conduct at the study sites but is not involved in data analysis. The Foundation reviewed and approved this manuscript for submission. Details regarding MJFF's Parkinson Progression Marker Initiative (PPMI) have been previously published (Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, et al. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95:629-35). Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article. Parkinson's Progression Markers Initiative authors are listed in the Appendix. Supporting information: Additional Supporting Information may be found in the online version of this article Additional Supporting Information may be found in the online version of this article at the publisher's web-site. CAPTION(S): Supplementary Information
Somatotropin ; Batteries ; Cognition ; Depression (Mood Disorder) ; Prevalence Studies (Epidemiology)
Cengage Learning, Inc.